Eli Lilly (NYSE: LLY) has achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China.
This development, confirmed through the company’s official WeChat account, represents a significant expansion in Eli Lilly’s global footprint.
The approval was granted by the National Medical Products Administration (NMPA), China’s regulatory authority for pharmaceuticals.
Mounjaro is designed for individuals with a body mass index (BMI) greater than 24 kg/m² and at least one related medical condition, providing a new option for weight management.
Eli Lilly had previously received approval for Tirzepatide, its diabetes treatment, in March.
Recently, Novo Nordisk, a key competitor, also gained approval for its weight loss drug, Wegovy.
The timing of Mounjaro’s approval highlights the competitive landscape in the burgeoning weight loss market.
Rising demand and market potential
The demand for weight loss medications surged following the popularity of Novo Nordisk’s Ozempic, which sparked a weight loss revolution.
According to Goldman Sachs analysts, the market for weight loss drugs could reach $100 billion by 2030.
Eli Lilly’s stock has risen 46% year-to-date, while Novo Nordisk’s shares are up 28%, reflecting the growing investor interest in this sector.
Competitors in the weight loss space
While Eli Lilly and Novo Nordisk currently lead the market, several competitors are developing their own weight loss solutions. Here’s a snapshot of how they measure up:
Viking Therapeutics
Viking Therapeutics is advancing both a weight loss pill and an injection. The pill has shown an average weight loss of 3.3% over 28 days, while the injection has resulted in a 14.7% weight loss over 13 weeks. The pill is in mid-stage trials and may reach the market before the injection, but it is not expected to challenge Eli Lilly’s dominance in the near term.
Amgen
Amgen’s MariTide differs from other weight loss drugs as it is administered monthly rather than weekly and uses an antibody-drug conjugate. Initial trials indicate that patients lose over 14.5% of their body weight in 12 weeks. Its unique administration method could provide a competitive edge.
Altimmune
Altimmune’s pemvidutide has shown results comparable to Novo Nordisk’s Wegovy. Additionally, it reduces muscle loss, a common side effect of weight loss drugs. Currently in mid-stage trials, pemvidutide is expected to gain FDA approval by the end of the year, but its impact on the market will depend on final results and approval timelines.
AstraZeneca and Eccogene
AstraZeneca is collaborating with Chinese biotech company Eccogene on a weight loss drug. Although the drug is several years away from market introduction, its anticipated competitive pricing strategy has already generated significant interest. The unique pricing model could potentially disrupt the market once the drug is available.
Future outlook and market dynamics
The weight loss drug market is highly competitive, with nearly every pharmaceutical company pursuing innovations in this area. Eli Lilly’s ability to maintain its pace of innovation will be crucial in sustaining its market leadership. While the company is currently well-positioned, it must remain vigilant as new, potentially more effective treatments enter the market.
As the industry evolves, Eli Lilly’s strategic moves and continuous innovation will determine its ability to stay ahead of the competition in the dynamic and rapidly growing weight loss sector.
The post Eli Lilly secures weight loss drug approval in China: How do rivals stack up? appeared first on Invezz
